1887
1 - The 3rd Annual International Conference on Information and Sciences
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

Gestational diabetes is a condition that occurs during the latter stages of pregnancy and is marked by notable resistance to insulin due to the release of hormones by the placenta. Zinc alpha 2-glycoprotein (ZAG) is an intriguing protein due to its ability to perform numerous essential functions in the human body. Prior research has linked ZAG to lipid metabolism.

This study was designed to evaluate the ZAG level in GDM pregnant women undergoing different therapeutic modalities. Furthermore, the study examines the correlation between ZAG and lipid parameters.

The study included a sample of 76 pregnant women aged 18 to 40 years. A total of 22 pregnant women without any health issues (Group 1), 30 pregnant women recently diagnosed with GDM (Group 2), and 24 pregnant women with GDM who were receiving various treatments (Group 3) were included in the study. All participants were in their second or third trimester of pregnancy, and their demographic information and lipid measurements were assessed.

There was no statistically significant difference in ZAG levels among study groups (P ≥ 0.05); hence, GDM pregnant women in Group 2 showed the highest level. In GDM pregnant women who received treatment, there was a significant difference in ZAG levels among subgroups (p<0.01). The metformin group had the lowest level of ZAG. The high-density lipoprotein and triglyceride levels were significantly higher in GDM-pregnant women in Groups 2 and 3 (p<0.05). Only in Group 3, ZAG levels and other lipid parameters (total cholesterol, high-density lipoprotein, low-density lipoprotein, triglyceride, and very low-density lipoprotein) were highly statistically significantly correlated with each other (p<0.01), except for triglyceride levels, where there was no correlation between them (p≥0.05).

The current findings revealed that ZAG levels are altered in GDM pregnant women and are beneficial indicators for metabolic status during treatment. ZAG levels correlate well with the lipid profile in GDM pregnant women who received treatment.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2024.cism.9
2024-01-24
2024-07-11
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2024/1/jemtac.2024.cism.9.html?itemId=/content/journals/10.5339/jemtac.2024.cism.9&mimeType=html&fmt=ahah

References

  1. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The Pathophysiology of Gestational Diabetes Mellitus. Int J Mol Sci. 2018 Oct 26; 19:(11):3342. doi: 10.3390/ijms19113342.
    [Google Scholar]
  2. Vince K, Perković P, Matijević R. What is known and what remains unresolved regarding gestational diabetes mellitus (GDM). J Perinat Med. 2020 Oct 25; 48:(8):757-763. doi: 10.1515/jpm-2020-0254.
    [Google Scholar]
  3. Lemaitre M, Ternynck C, Bourry J, Baudoux F, Subtil D, Vambergue A. Association Between HbA1c Levels on Adverse Pregnancy Outcomes During Pregnancy in Patients With Type 1 Diabetes. J Clin Endocrinol Metab. 2022 Feb 17; 107:(3):e1117-e1125. doi: 10.1210/clinem/dgab769.
    [Google Scholar]
  4. Antwi-Baffour S, Kyeremeh R, Boateng SO, Annison L, Seidu MA. Haematological parameters and lipid profile abnormalities among patients with Type-2 diabetes mellitus in Ghana. Lipids Health Dis. 2018 Dec 13; 17:(1):283. doi: 10.1186/s12944-018-0926-y.
    [Google Scholar]
  5. Herrera E, Desoye G. Maternal and fetal lipid metabolism under normal and gestational diabetic conditions. Horm Mol Biol Clin Investig. 2016 May 1; 26:(2):109-27. doi: 10.1515/hmbci-2015-0025.
    [Google Scholar]
  6. Rahnemaei FA, Pakzad R, Amirian A, Pakzad I, Abdi F. Effect of gestational diabetes mellitus on lipid profile: A systematic review and meta-analysis. Open Med (Wars). 2021 Dec 15; 17:(1):70-86. doi: 10.1515/med-2021-0408.
    [Google Scholar]
  7. Banaszak M, Górna I, Przysławski J. Zinc and the Innovative Zinc-α2-Glycoprotein Adipokine Play an Important Role in Lipid Metabolism: A Critical Review. Nutrients. 2021 Jun 11; 13:(6):2023. doi: 10.3390/nu13062023.
    [Google Scholar]
  8. Stejskal D, Karpísek M, Reutová H, Stejskal P, Kotolová H, Kollár P. Determination of serum zinc-alpha-2-glycoprotein in patients with metabolic syndrome by a new ELISA. Clin Biochem. 2008 Mar; 41:(4-5):313-6. doi: 10.1016/j.clinbiochem.2007.11.010.
    [Google Scholar]
  9. Russell ST, Tisdale MJ. Mechanism of attenuation of skeletal muscle atrophy by zinc-alpha2-glycoprotein. Endocrinology. 2010 Oct; 151:(10):4696-704. doi: 10.1210/en.2010-0532.
    [Google Scholar]
  10. Elattar S, Dimri M, Satyanarayana A. The tumor secretory factor ZAG promotes white adipose tissue browning and energy wasting. FASEB J. 2018 Sep; 32:(9):4727-4743. doi: 10.1096/fj.201701465RR.
    [Google Scholar]
  11. Xiao XH, Qi XY, Wang YD, Ran L, Yang J, Zhang HL, et al. Zinc alpha2 glycoprotein promotes browning in adipocytes. Biochem Biophys Res Commun. 2018 Feb 5; 496:(2):287-293. doi: 10.1016/j.bbrc.2018.01.039.
    [Google Scholar]
  12. Gong FY, Zhang SJ, Deng JY, Zhu HJ, Pan H, Li NS, et al. Zinc-alpha2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. Int J Obes (Lond). 2009 Sep; 33:(9):1023-30. doi: 10.1038/ijo.2009.141.
    [Google Scholar]
  13. Xiang AH, Takayanagi M, Black MH, Trigo E, Lawrence JM, Watanabe RM, et al. Longitudinal changes in insulin sensitivity and beta cell function between women with and without a history of gestational diabetes mellitus. Diabetologia. 2013 Dec; 56:(12):2753-60. doi: 10.1007/s00125-013-3048-0.
    [Google Scholar]
  14. Xu D, You J, Chen G, Su H, Zhang L, Cui L, et al. Changes of Serum Zinc-α2-Glycoprotein Level and Analysis of Its Related Factors in Gestational Diabetes Mellitus. J Diabetes Res. 2021 Feb 18; 2021::8879786. doi: 10.1155/2021/8879786.
    [Google Scholar]
  15. Wang J, Li Z, Lin L. Maternal lipid profiles in women with and without gestational diabetes mellitus. Medicine (Baltimore). 2019 Apr; 98:(16):e15320. doi: 10.1097/MD.0000000000015320.
    [Google Scholar]
  16. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005 May-Jun; 36:(3):232-40. doi: 10.1016/j.arcmed.2005.01.005.
    [Google Scholar]
  17. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015 May; 58:(5):886-99. doi: 10.1007/s00125-015-3525-8.
    [Google Scholar]
  18. Ryckman KK, Spracklen CN, Smith CJ, Robinson JG, Saftlas AF. Maternal lipid levels during pregnancy and gestational diabetes: a systematic review and meta-analysis. BJOG. 2015 Apr; 122:(5):643-51. doi: 10.1111/1471-0528.13261.
    [Google Scholar]
  19. Mankuta D, Elami-Suzin M, Elhayani A, Vinker S. Lipid profile in consecutive pregnancies. Lipids Health Dis. 2010 Jun 5; 9::58. doi: 10.1186/1476-511X-9-58.
    [Google Scholar]
  20. Yang M, Liu R, Li S, Luo Y, Zhang Y, Zhang L,et al. Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes. Diabetes Care. 2013 May; 36:(5):1074-82. doi: 10.2337/dc12-0940.
    [Google Scholar]
  21. Liao X, Wang X, Li H, Li L, Zhang G, Yang M, et al. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes. Sci Rep. 2016 Sep 9; 6::32887. doi: 10.1038/srep32887.
    [Google Scholar]
  22. Alenad AM, Alkaltham LF, Sabico S, Khattak MNK, Wani K, Al-Daghri NM, et al. Associations of zinc-α-2-glycoprotein with metabolic syndrome and its components among adult Arabs. Sci Rep. 2022 Mar 22; 12:(1):4908. doi: 10.1038/s41598-022-09022-1.
    [Google Scholar]
  23. Näf S, Escote X, Yañez RE, Ballesteros M, Simón I, Gil P, et al. Zinc-α2-glycoprotein is unrelated to gestational diabetes: anthropometric and metabolic determinants in pregnant women and their offspring. PLoS One. 2012; 7:(12):e47601. doi: 10.1371/journal.pone.0047601.
    [Google Scholar]
  24. Yeung DC, Lam KS, Wang Y, Tso AW, Xu A. Serum zinc-alpha2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in Chinese subjects. J Clin Endocrinol Metab. 2009 Jul; 94:(7):2531-6. doi: 10.1210/jc.2009-0058.
    [Google Scholar]
  25. Lei L, Li K, Li L, Fang X, Zhou T, Zhang C, et al. Circulating zinc-α2-glycoprotein levels are low in newly diagnosed patients with metabolic syndrome and correlate with adiponectin. Nutr Metab (Lond). 2017 Aug 14; 14::53. doi: 10.1186/s12986-017-0210-6.
    [Google Scholar]
  26. Rajabi S, Mazloom Z, Zamani A, Tabatabaee HR. Effect of Low Glycemic Index Diet Versus Metformin on Metabolic Syndrome. Int J Endocrinol Metab. 2015 Oct 17; 13:(4):e23091. doi: 10.5812/ijem.23091.
    [Google Scholar]
  27. Lin SH, Cheng PC, Tu ST, Hsu SR, Cheng YC, Liu YH. Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed type 2 diabetes mellitus: a cohort study. PeerJ. 2018 Apr 12; 6::e4578. doi: 10.7717/peerj.4578.
    [Google Scholar]
  28. Marrades MP, Martínez JA, Moreno-Aliaga MJ. ZAG, a lipid mobilizing adipokine, is downregulated in human obesity. J Physiol Biochem. 2008 Mar; 64:(1):61-6. doi: 10.1007/BF03168235.
    [Google Scholar]
/content/journals/10.5339/jemtac.2024.cism.9
Loading
/content/journals/10.5339/jemtac.2024.cism.9
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error